Ascletis Pharma Inc.

Investors

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023
2023-02-02
Voluntary Announcement - Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
2023-01-31
Voluntary Announcement - Ascletis Announces IND Approval of ASC10 for Monkeypox Indication by China NMPA
2023-01-26
Voluntary Announcement - Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere
2023-01-17
Voluntary Announcement - Ascletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19
2023-01-16
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
2023-01-05
Announcement - Legal Proceedings Involving the Group
2023-01-02
Grant of Share Options
2022-12-30
Voluntary Announcement - Ascletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Inhibitor ASC10 and Its Derivatives
2022-12-19
Voluntary Announcement - Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19
2022-12-12

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1